On September 9, 2026, LifeTech Scientific Corporation (01302.HK) received formal notification from China’s National Medical Products Administration (NMPA) that its Lantval™ Aortic Valve Replacement System had been admitted to the Special Examination and Approval Procedure for Innovative Medical Devices.

The product was jointly developed by LifeTech subsidiary Shenzhen Jianxin Medical Technology Co., Ltd. and Fuwai Hospital, Chinese Academy of Medical Sciences, National Center for Cardiovascular Diseases.

Lantval is intended for the surgical treatment of patients with aortic stenosis or aortic stenosis accompanied by regurgitation. It is LifeTech’s 18th product to enter the NMPA innovative medical device pathway.

Unlike TAVR, Lantval remains a surgical aortic valve replacement product. However, it incorporates a self-expanding sutureless anchoring mechanism intended to simplify conventional SAVR implantation.

According to LifeTech, Lantval also incorporates the company’s proprietary dry-tissue processing technology and a fully preloaded, ready-to-use design. The product completed its first-in-human (FIM) study in 2025, and its pre-market registration clinical study is expected to begin next.

This Is Not TAVR, but It Is Also Different From Conventional Surgical Valve Replacement

Over the past decade, TAVR has transformed the treatment landscape for aortic stenosis by allowing aortic valve replacement without open-heart surgery.

However, conventional surgical aortic valve replacement (SAVR) remains widely used, particularly in patients who require removal of heavily calcified native valve tissue, concomitant cardiac procedures or other surgical treatment.

SAVR also retains several established advantages, including direct removal of the diseased native valve and long-term clinical experience with surgical bioprosthetic valves.

One of the procedural burdens, however, is implantation.

Conventional surgical valves generally require multiple sutures to secure the prosthesis to the native annulus. This process contributes to aortic cross-clamp and cardiopulmonary bypass time and adds technical steps to the procedure.

Sutureless valves and rapid-deployment valves were developed partly to reduce this implantation burden.

Lantval falls into this broader category, but its product design combines several features in one platform: sutureless anchoring, a fully preloaded configuration and dry bioprosthetic valve tissue.

Why Does Conventional SAVR Require So Many Sutures?

In conventional surgical aortic valve replacement, the surgeon first exposes the heart, establishes cardiopulmonary bypass and cross-clamps the aorta.

After the diseased native valve is excised and calcification is removed, the prosthetic valve usually needs to be secured around the aortic annulus with multiple sutures.

Depending on the surgical technique and valve type, implantation can require roughly 12–15 annular sutures.

Each suture needs to be placed at an appropriate position and tension, and the prosthesis must be seated accurately before the sutures are tied.

This contributes to procedural complexity and affects the duration of aortic cross-clamping.

For more complex patients, particularly those undergoing combined procedures, reducing implantation time can become more important.

Sutureless valves and rapid-deployment valves were developed to simplify this part of SAVR.

How Does Lantval Work?

Lantval’s product concept combines elements associated with both SAVR and TAVR.

It retains key characteristics of SAVR

The native diseased valve can still be surgically removed, allowing direct treatment of calcified tissue.

The implantation is performed under direct surgical visualization, and the valve is positioned within the surgically prepared annulus.

It incorporates a TAVR-like self-expanding anchoring mechanism

Instead of relying primarily on multiple annular sutures, Lantval uses a self-expanding support structure to anchor the prosthetic valve.

This is intended to reduce the number of implantation steps required during surgical valve replacement.

LifeTech describes the system as combining the advantages of SAVR — including removal of the native calcified valve and established hemodynamic performance — with the self-expanding, sutureless anchoring principle used in transcatheter valve technology.

Lantval also incorporates two additional design features.

First, it is fully preloaded. The valve is supplied already mounted on the delivery system, reducing preparation steps before implantation.

Second, it uses a dry-valve design. The bioprosthetic tissue does not require the same conventional liquid-storage preparation process before implantation.

According to LifeTech, the combination of these technologies is intended to support rapid implantation through minimally invasive surgical access.

The “Dry Valve” Is Intended to Do More Than Support Sutureless Implantation

One of Lantval’s more distinctive features is its dry-tissue processing technology.

Traditional bioprosthetic heart valves are commonly stored in liquid preservation solutions and require preparation before implantation.

LifeTech developed a proprietary dry-membrane treatment process for Lantval.

The company says the technology is intended to improve storage and handling of the biological valve tissue while also supporting long-term durability.

The fully preloaded dry-valve format also allows the valve to be supplied in a ready-to-use configuration.

From an operating-room workflow perspective, this could reduce preparation steps before implantation.

However, the longer-term performance of the dry-tissue technology will ultimately require clinical follow-up.

At this stage, the main available evidence comes from the company’s early clinical development program, while larger registration studies are still pending.

FIM Has Been Completed, but Key Clinical Data Have Not Yet Been Fully Published

LifeTech said Lantval completed its first-in-human (FIM) clinical study in 2025.

According to the company, valve implantation time was significantly shorter than with conventional surgical valve replacement, all participants completed follow-up for the primary endpoints, and postoperative recovery and quality of life were favorable.

LifeTech said the study provided preliminary evidence of the engineering and clinical feasibility of its integrated “dry valve + fully preloaded + sutureless” design.

The company has also stated that the system may simplify implantation, shorten valve implantation time, reduce the risk of paravalvular leakage and improve hemodynamic performance and valve durability. These claims currently remain company-reported conclusions from early-stage clinical development.

More detailed clinical information has not yet been fully disclosed publicly.

Important data still include the study population, detailed procedural times, valve gradients, paravalvular leak rates, pacemaker implantation rates and longer-term structural valve performance.

Lantval’s pre-market registration clinical study is expected to begin next, which will provide a larger dataset for evaluating safety and effectiveness.

Sutureless Surgical Aortic Valves Already Have More Than a Decade of Commercial History

Lantval is entering a field that already has an established international product history.

One of the best-known sutureless surgical valves is the Perceval™ platform, originally developed by Sorin and now marketed by Corcym.

The Perceval platform has been used clinically since 2007 and uses a self-expanding frame to support sutureless implantation. Corcym currently markets Perceval™ Plus Lancelot.

Another major product is the EDWARDS INTUITY Elite valve system from Edwards Lifesciences.

INTUITY Elite is classified as a rapid-deployment surgical valve rather than a fully sutureless system. It incorporates transcatheter-derived anchoring technology while using guiding sutures during implantation.

The system received FDA approval in 2016 and is designed to streamline SAVR procedures and facilitate smaller-incision approaches.

These products illustrate how surgical valve technology has continued to evolve even as TAVR has expanded rapidly.

The technical objective is broadly similar: retain the advantages of surgical valve replacement while reducing implantation complexity and shortening procedure-related time.

Lantval enters this segment with a somewhat different combination: sutureless implantation + fully preloaded delivery + dry-valve technology.

LifeTech Extends Its Structural Heart Portfolio

Lantval also represents an extension of LifeTech’s product portfolio from interventional structural heart technologies into surgical valve replacement.

LifeTech has built much of its cardiovascular business around minimally invasive interventional devices.

Lantval, by contrast, is a surgically implanted product.

This expands the company’s valve strategy beyond transcatheter treatment and into the surgical pathway.

As of June 30, 2026, LifeTech reported more than 2,600 global patents, while Lantval became the company’s 18th product admitted to China’s innovative medical device special review procedure.

The company’s structural heart portfolio is therefore increasingly spanning multiple treatment approaches rather than a single access route.

For Lantval, the immediate next step is the registration clinical program.

Its eventual position in the market will depend not only on whether implantation can be simplified, but also on longer-term hemodynamic performance, safety, durability and how the product compares with established conventional surgical valves, sutureless systems and rapid-deployment valves.

TAVR Is Growing Rapidly, but Surgical Valves Are Still Evolving

The rapid expansion of TAVR has changed the treatment of aortic stenosis, particularly among older and higher-risk patients.

But this does not mean surgical valve replacement has stopped evolving.

SAVR remains relevant for patients who require direct removal of calcification, concomitant cardiac procedures or other conditions where surgery remains appropriate.

The development of minimally invasive SAVR, sutureless valves and rapid-deployment valves reflects an effort to reduce some of the procedural burdens associated with traditional surgery.

Lantval follows this direction but attempts to combine several elements in one system: sutureless anchoring, dry-valve technology, full preloading and minimally invasive surgical implantation.

Its entry into the NMPA innovative medical device pathway is a regulatory milestone, but the product has not yet reached the market.

The next stage will be more important for assessing its clinical position.

With the registration study set to begin, future evidence will need to clarify implantation time, hemodynamics, conduction-related complications, paravalvular leakage, long-term durability and overall safety.

For now, Lantval represents another example of how surgical aortic valve technology continues to evolve alongside TAVR rather than simply being replaced by it.

September 11, 2026